SHANGHAI – Cayman-registered Hutchison China Meditech Ltd. has updated its SEC F-1 filing for a third time since it announced its intention to go public in the U.S. under the stock ticker HCM.
SHANGHAI – Sciclone Pharmaceuticals Inc., of Foster City, Calif., will pay $12.8 million to settle charges that it violated the Foreign Corrupt Practices Act (FCPA) when its international subsidiaries reportedly increased sales by making improper payments to health care professionals employed at state health institutions in China.
SHANGHAI – Cayman-registered Hutchison China Meditech Ltd. has updated its SEC F-1 filing for a third time since it announced its intention to go public in the U.S. under the stock ticker HCM. There is a wealth of financial and scientific data to pore over, as one of China’s first biotechs Hutchison has a multipronged business that includes 19 active studies for seven clinical-stage therapies for oncology and immunological diseases, licensing deals with big pharma and diversified commercial operations for prescription and OTC drugs. But the one item still missing from the prospectus is a share price.
SHANGHAI – Suzhou, China-based Adagene Inc. received $28 million in series B financing to further enhance its technology-driven antibody discovery platform and nudge its own portfolio of innovative antibodies, against targets related to cancer and other diseases, closer to the clinic.
SHANGHAI – Suzhou, China-based Adagene Inc. received $28 million in series B financing to further enhance its technology-driven antibody discovery platform and nudge its own portfolio of innovative antibodies, against targets related to cancer and other diseases, closer to the clinic.
SHANGHAI – Glaxosmithkline plc's China problem has taken a new turn. Two employees, both scientists of Chinese heritage, have been indicted by a federal grand jury in Pennsylvania on criminal charges for stealing early stage biologic secrets from GSK.
SHANGHAI – Beijing-based oncology drug developer Beigene Co. Ltd. updated plans for its Nasdaq IPO, seeking to issue 5.5 million American depository shares, representing 71.5 million ordinary shares, priced between $22 to $24 per share, which would bring in $126.5 million at the midpoint, up from the $100 million stated in its initial SEC filing in October.
SHANGHAI – Glaxosmithkline plc’s China problem has taken a new turn. Two employees, both scientists of Chinese heritage, have been indicted by a federal grand jury in Pennsylvania on criminal charges for stealing early stage biologic secrets from GSK.
SHANGHAI – Beijing-based oncology drug developer Beigene Co. Ltd. updated plans for its Nasdaq IPO, seeking to issue 5.5 million American depository shares, representing 71.5 million ordinary shares, priced between $22 to $24 per share, which would bring in $126.5 million at the midpoint, up from the $100 million stated in its initial SEC filing in October.
SAN FRANCISCO – The J.P. Morgan Healthcare Conference might be reluctant to change, dedicated to the same (crowded) hotel venue for the past 34 years, but it is open to a rapidly growing group of attendees, with last week's meeting inviting a substantial number of people from China.
